3 Monster Stocks for the Next 10 Years

Have a little money and a lot of time? Say, ten years or more? That's perfect. Time is the best friend of investors, and of course, the more money you have to deploy, the greater your potential net return. And, if you have at least a decade to work with, you have time to take a lens on some relatively volatile but potentially revolutionary investment prospects.

With this as a background, this is the acquisition of three monster stocks, even if it doesn't take longer, to buy and hold for 10 years. Please note that each of them is not only in a brand new business. They have greatly promoted the formation of their respective industries.

Where to invest $1,000 now? Our team of analysts just revealed what they think is 10 Best Stocks Buy it now. continue”

Ten years ago, the idea of ​​connecting a stranger who needed to ride a bike with another stranger (using the driver's own vehicle, no less than) seemed to be unsold. This seems outrageous. However, the ride-hailing business proved to be a brilliant idea driven by a major socio-cultural movement and it didn’t become clear until a few years later.

In short, people are interested in driving or even owning their own car. According to the Federal Highway Administration, the number of 19-year-olds with driver's licenses in the United States has dropped from 87% in 1983 to below 69% in 2022. Differences are even differences among young teenagers. Less than 40% of qualified teenagers living in the United States have a driver’s license, compared with about two-thirds of this group three decades ago.

Similarly, a recent survey by Deloitte shows that while only 11% of U.S. residents aged 55 and older would consider giving up their cars, at least 44% of at least 35 years of age are willing to accept the idea given their willingness to use other modes of transportation.

Connection point. Young consumers are more satisfied with the new ways of doing things. As they age, they will further normalize this alternative mobility model.

Enter Uber Technology (NYSE: Uber)which dominates the domestic ride business, but has also opened stores overseas and is also not interested in driving and vehicle ownership. The highest growth rate last year was 18% to $44 billion, extending a long-term trend that is expected to last at this rate for at least a few years.

However, this growth trend may last longer, not just a few years. Market Research Clothing Companies Coherent Market Insights believes that the global ride market age will grow by 13.5% annualized to 2032. As a market leader, Uber is in a good position to take up a fair share of this long-term growth. That's why stocks have performed since the beginning of last year.

Given the progress made by AI in the past few years, most investors may agree that it is only a matter of time before using AI to create new drugs. However, most people may not realize it is happening. A company called Recursive Pharmaceuticals (NASDAQ: RXRX) Such development tools are currently used and provided to third-party pharmaceutical companies.

It is called a recursive operating system. Like any other ordinary LLM (big language model) AI platform, the platform can filter large amounts of digital data and then combine context-sensitive information. It can then determine how new therapeutic molecules are assembled and then test how they are treated as a treatment for a specific disease.

As you might guess, the main advantages of this approach over more traditional drug research are: speed and cost. Traditional pharmacy R&D efforts can take years and millions of dollars to complete trials that end in failure, but AI-based testing can be completed almost a fraction of the cost in weeks, if not days. This means that the pharmaceutical industry can afford more swings, even knowing that most may end up in failure.

It can be clearly seen that the recursive business is dual-tube. It not only shares revenue with third-party pharmaceutical companies currently included to access its platform Luo's,,,,, Bayerand Sanofibut it is also working on some of its own stuff. All in all, nearly a dozen drugs conceived and digitally tested in recursive OS are now in practical, required clinical trials. In clinical testing, others were eliminated before wasting time and money.

But, this is still just the beginning. Global Market Insights predicts that the average annual rate of AI-powered drug discovery business will grow by almost 30% from now until 2032. Recursive drugs are currently unprofitable. However, given the industry-wide headwind, profitability is easily visible in the card for the next 10 years, so this stock pops up.

Finally, add ionq (NYSE: IONQ) List of potential clients that can eliminate monster-sized returns over the next decade. You may be familiar with how traditional computing devices, such as the one you are using now, work. A lot of digital information is competing around computer chips and converting it into a form that you can see and interact comfortably.

However, despite the impressive technology, the underlying binary code of the technology is beyond the digital binary code, while zero is actually somewhat limited. There is a stronger option. By using subatomic particles as the basis, a so-called quantum computer can process large amounts of data. In fact, using quantum computing, it is now possible to complete calculations that may take decades to traditional computers.

Of course, this speed has a significant impact on industries such as artificial intelligence, cybersecurity and even the above-mentioned drug discovery.

There yes There is little problem with practicality and cost. For example, such platforms are too killer for everyday web browsing, and buying a browsing for heavy numbers can easily cost hundreds of thousands of dollars, or more. Even renting only cloud-based access to quantum computers can cost $50 per minute.

However, for the right purpose, many agencies can come up with such money, such as the U.S. Air Force, Busan City (South Korea) and the Application Research Laboratory of Intelligence and Security (or ARLIS). Now, these three organizations, along with several others, are testing IONQ's technology to figure out how best to take advantage of this powerful new computing option. The company did a $43 million business last year, which is actually a 95% increase from the top line in 2023.

But this still only scratches the surface. First, the study predicts that the global quantum computing industry will grow by 31% in compound interest years during 2034, which makes one exciting for (very) few “pure games”.

Before you buy stocks with IONQ, consider the following:

this Motley Fool Stock Advisor The analyst team just confirmed what they think is 10 Best Stocks Investors buy now…and IONQ is not one of them. Ten stocks with layoffs could generate monster returns in the coming years.

When to consider Netflix On this list on December 17, 2004…If you invested $1,000 when you suggested, You will have $561,046! * Or when Nvidia This list was listed on April 15, 2005…If you invested $1,000 when you suggested, You will have $606,106! *

Now, it's worth noting Stock ConsultantThe overall average return is 811% – Compared to market impulses 153% For the S&P 500 index. Don't miss the latest top ten list, available when you join Stock Consultant.

View 10 stocks »

*Stock consultant returns as of April 21, 2025

James Brumley has no position in any of the stocks mentioned. Motley fool has a place and recommends Uber technology. Motley Fool recommends Roche Holding AG. Motley Fool has a disclosure policy.

Motley Fool originally published 3 Monster Stocks held in 3 years